Abstract
Copyright: © 2013 Fan LC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Non-cystic fibrosis bronchiectasis is a respiratory disease characterized by persistent airway inflammation and dilation of bronchial wall driven by diverse etiology [1]. Patients with bronchiectasis suffer a lot from sputum production, recurrent exacerbations, and progressive airway destruction [2]. From 2000 to 2007, the prevalence of bronchiectasis in the United States was 1,106 cases per 100,000 people with an annual percentage increase of 8.74% [3]. The average annual hospitalization rate was 9.4 per 100,000 populations in Germany during 2005-2011, with the highest rate of 39.4 hospitalizations per 100,000 populations among men aged 75-84 years [4].
Highlights
Non-cystic fibrosis bronchiectasis is a respiratory disease characterized by persistent airway inflammation and dilation of bronchial wall driven by diverse etiology [1]
At the end of the 6-month treatment period, the azithromycin group had a 62% relative reduction in rate of exacerbations compared to placebo
Quality of life measured by SGRQ and LRTI-VAS score both showed a larger decrease of the total score in azithromycin group compared with placebo at the end of treatment (p
Summary
Non-cystic fibrosis bronchiectasis is a respiratory disease characterized by persistent airway inflammation and dilation of bronchial wall driven by diverse etiology [1]. Reports showed that macrolides maintain therapy could reduce frequency of respiratory exacerbations, decreased 24 hour sputum volume and improved quality of life. In the EMBRACE trial, 141 patients were randomly assigned to two groups in a ratio of 1:1, receiving azithromycin 500 mg or placebo three times a week for 6 months and observed for the 6 months [7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
